Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition.

ABSTRACT: Acute myeloid leukaemia (AML) affects predominantly elderly people and has an incidence of 1% of all cancers and 2% of all cancer deaths. Despite using intensive chemotherapy and allogeneic stem cell transplantation, the treatment options for AML remain open for innovation. Thus, there is a need to explore alternative therapies such as less toxic targeted therapies in AML. Aurora A kinase is a well-established target for the treatment of various cancers, including AML. This kinase plays a pivotal role in the cell-division cycle, particularly in different stages of mitosis, and is also involved in many other cellular regulatory processes. In a previous study, we demonstrated that the anti-viral drug rilpivirine is an Aurora A kinase inhibitor. In the current study, we have further explored

SUBMITTER: Islam S 

PROVIDER: S-EPMC9954146 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature